Strasbourg, France, Apr. 22, 2024 – Syndivia, a leading biotechnology ADC (antibody-drug conjugates) company, is proud to announce the unveiling of a clinical asset showcasing its proprietary high-stability ADC linker technology (APN).
Developed in collaboration with Inatherys, this candidate marks a significant milestone in the field of oncology therapeutics. The new clinical asset, INA03, represents a potent transferrin-competitive antibody-drug conjugate with improved stability in plasma designed to target CD71, with the aim of revolutionizing acute leukemia treatment. This innovative ADC has been years in the making, with Syndivia and Inatherys jointly overcoming numerous challenges to bring this promising candidate into the clinic (ClinicalTrials.gov identifier: NCT03957915).